Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study.
about
Article-level metrics and the evolution of scientific impactOlfactory dysfunction predicts 5-year mortality in older adultsQuantifying cardiometabolic risk using modifiable non-self-reported risk factorsLow HbA1c and Increased Mortality Risk-is Frailty a Confounding Factor?Prevalence of hyperhomocysteinemia in China: a systematic review and meta-analysisCurrent and cumulative night shift work and subclinical atherosclerosis: results of the Gutenberg Health StudyA Cross-Sectional Study of the Cardiovascular Effects of Welding FumesThe contrasting relationships between betaine and homocysteine in two clinical cohorts are associated with plasma lipids and drug treatmentsEvidence for the free radical/oxidative stress theory of ageing from the CHANCES consortium: a meta-analysis of individual participant dataCommunity cardiovascular disease risk from cross-sectional general practice clinical data: a spatial analysis.Mortality Risk Prediction: Can Comorbidity Indices Be Improved With Psychosocial Data?The lipid profile and mortality risk in elderly type 2 diabetic patients: a ten-year follow-up study (ZODIAC-13).Association between plasma homocysteine concentration and the risk of all-cause death in adults with diastolic dysfunction in a community: A 13-year cohort studyAnalysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves.MicroRNAs are involved in homocysteine-induced cardiac remodeling.Homocysteine and familial longevity: the Leiden Longevity StudyPlasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study.Homocysteine and markers of inflammation in acute coronary syndromeDetection of homocysteine and C-reactive protein in the saliva of healthy adults: comparison with blood levelsAdding multiple risk factors improves Framingham coronary heart disease risk scores.Framingham risk score and alternatives for prediction of coronary heart disease in older adults.Health-related quality of life and mortality in a general and elderly population of patients with type 2 diabetes (ZODIAC-18).Betaine and secondary events in an acute coronary syndrome cohort.Predicting survival and morbidity-free survival to very old ageACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing.A quantile regression approach can reveal the effect of fruit and vegetable consumption on plasma homocysteine levels.Weak prediction power of the Framingham Risk Score for coronary artery disease in nonagenarians.Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at RiskThe homocysteine controversyPredictive value of a profile of routine blood measurements on mortality in older persons in the general population: the Leiden 85-plus StudyBetaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational StudyA summary risk score for the prediction of Alzheimer disease in elderly personsUnanswered clinical questions in the management of cardiometabolic risk in the elderly: a statement of the Spanish Society of Internal Medicine.Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study.Relationship of MTHFR gene polymorphisms with renal and cardiac diseaseNT-proBNP best predictor of cardiovascular events and cardiovascular mortality in secondary prevention in very old age: the Leiden 85-plus StudyTo screen or not to screen for peripheral arterial disease in subjects aged 80 and over in primary health care: a cross-sectional analysis from the BELFRAIL study.In vivo noninvasive measurement of skin autofluorescence biomarkers relate to cardiovascular disease in mice.Shared decision making in type 2 diabetes with a support decision tool that takes into account clinical factors, the intensity of treatment and patient preferences: design of a cluster randomised (OPTIMAL) trial.The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis.
P2860
Q21092728-26050A55-C6AE-49E2-9DD3-DB79A0F57C40Q21131947-9CAA40C2-BDBF-45AA-9E60-F5C1D916396FQ24169777-30C8646A-D3F3-4808-A8B0-4D1EC63A533BQ26799903-4A03D607-CB78-4A29-BC93-F5EF1E51B0EFQ28386310-B69EEA19-31BB-40F0-AC59-B4981F28B7F6Q28390977-8D6D4A46-DD9A-4E36-86C2-3C670DEBB8C6Q28397849-982BFBDE-F085-46BE-81F3-CA90D919364BQ28481369-FADD9E98-CA42-4CE5-A85A-A43451ED56BAQ28604259-BA2A82AF-E0DC-4834-942F-9ADFC70A53E4Q30900391-C5F4E796-D2FC-4081-B759-67B6E716BACBQ30999448-A83301DB-8EFA-465B-936C-CD3DD4C1EDF2Q33521206-9E29C468-1084-47CC-B5D5-2CE35436908BQ33627168-4FB2FB76-AB51-4AD8-A5A8-790EF9D15556Q33729360-68A2F31B-8957-4E83-A2FC-4162B6AF0268Q33824386-071ED67F-E6A2-4861-BA15-EFBAB9910268Q33847594-74D5F427-5742-46A0-8BCE-22820A550C61Q33848664-F876A5CD-432A-4E1A-8BE4-339FB7701D76Q33967764-1A566723-ECDF-43DD-8843-25B9E787C7BCQ34052672-0149597A-9B5C-4041-9BC1-F77236106F6CQ34173016-F80A6BA2-6471-4418-A3CE-FEB30D2B1703Q34217860-CDE1A982-A507-4D87-8EA2-10F2A01AC92AQ34237379-CB67254F-16A1-45D1-9597-ADFA46A84D00Q34287613-6E5B0CBC-5B03-4376-B4FE-181C73BAB0DFQ34306423-46FA293E-EFC4-405C-AC7A-7FE13FBB2230Q34320780-DF2027F8-B451-49B6-A6E3-6C84C234D4DAQ34445589-FAFBAD79-A79D-4A95-9100-2B41E6825E50Q34506768-82D87478-8F6C-435D-9D35-804652849365Q34516430-A33E6BA9-1127-46F3-9CFB-CADBFC06406DQ34519563-6468E104-9860-477C-9E22-93619D9D9CADQ34618569-84903B5E-55D8-4001-AEF1-B07E1EB09BB6Q34672965-14E4949C-298A-49C6-9A63-31E2B07C4334Q34747831-88CADCD0-031B-4470-AF29-E7416775E8DCQ34901444-AF2E9AEC-A053-4283-9DD9-2C40F507B0E0Q35021094-3E6B433D-3FAE-488C-8DC7-BB957120D37AQ35050801-FE11A85A-8F4F-4B1F-B944-E4F6E977F893Q35054042-1F480519-8BE7-4CDF-ABD7-73A81BD8BCB1Q35063654-79F85159-E588-4862-BEEC-BA56713FADF9Q35165724-157B0801-A7C0-49BB-80B5-0671208E1D74Q35206656-9F019AC5-22F8-45DC-9A99-029681CD624BQ35557044-96B49663-6B2D-4296-BE29-54691F79BCCC
P2860
Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of Framingham risk score a ...... ed observational cohort study.
@en
Use of Framingham risk score a ...... ed observational cohort study.
@nl
type
label
Use of Framingham risk score a ...... ed observational cohort study.
@en
Use of Framingham risk score a ...... ed observational cohort study.
@nl
prefLabel
Use of Framingham risk score a ...... ed observational cohort study.
@en
Use of Framingham risk score a ...... ed observational cohort study.
@nl
P2093
P2860
P50
P356
P1433
P1476
Use of Framingham risk score a ...... sed observational cohort study
@en
P2093
Anton J M de Craen
Jacobijn Gussekloo
Rudi G J Westendorp
Wouter de Ruijter
P2860
P356
10.1136/BMJ.A3083
P407
P577
2009-01-08T00:00:00Z